IP Library Granted Patent US 7,063,954
Granted Patent B2
US 7,063,954 · App. 10/649,852 · Granted Jun 20, 2006

Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,063,954
App. No.
10/649,852
Granted
Jun 20, 2006
Kind
B2
Abstract

Screening methods for identifying compounds that bind to or activate corticotropin releasing factor 2 receptors (CRF 2 R) and regulate or potentially regulate skeletal muscle mass or function in vivo are disclosed. Also disclosed are screening methods for identifying compounds that prolong or augment the activation of CRF 2 Rs or of CRF 2 R signal transduction pathways, increase CRF 2 R or increase CRF expression are provided. Pharmaceutical compositions comprising CRF 2 R agonists, antibodies to CRF 2 R and methods for increasing skeletal muscle mass or function or for the treatment of skeletal muscle atrophy using CRF 2 R as the target for intervention and methods for treatment of muscular dystrophies are described.

Claims (19)

1. A method for identifying candidate compounds for regulating skeletal muscle mass or function, comprising:

a. contacting a test compound with a vertebrate CRF 2 R;

b. determining whether the test compound binds to or activates the CRF 2 R;

c. selecting those compounds that bind or activate CRF 2 R, and further determining whether the test compound regulates muscle mass or function in a skeletal muscle atrophy model system; and

d. identifying those test compounds that regulate muscle mass or function as candidate compounds for regulating skeletal muscle mass or function.

2. The method for identifying candidate compounds according to claim 1 , in which the CRF 2 R is expressed on a eukaryotic cell.

3. The method for identifying candidate compounds according to claim 1 wherein the CRF 2 R has the amino acid sequence corresponding to the amino acid sequence of SEQ ID NO: 32.

4. The method for identifying candidate compounds according to claim 2 , in which determining whether the test compound activates the CRF 2 R involves measuring the cellular cAMP level.

5. The method for identifying candidate compounds according to claim 4 , in which the cell further comprises a reporter gene operatively associated with a cAMP responsive element and measuring the cellular cAMP level involves measuring expression of the reporter gene.

6. The method for identifying candidate compounds according to claim 5 , in which the reporter gene is alkaline phosphatase, chloramphenicol acetyltransferase, luciferase, glucuronide synthetase, growth hormone, placental alkaline phosphatase, or Green Fluorescent Protein.

7. A method for identifying candidate compounds for regulating skeletal muscle mass or function comprising:

a. contacting a test compound with a cell expressing a functional vertebrate CRF 2 R, and determining level of activation of CRF 2 R resulting from the test compound;

b. contacting said test compound with a cell expressing a functional vertebrate CRF 1 R, and determining level of activation of CRF 1 R resulting from the test compound;

c. comparing the level of CRF 2 R activation and the level of CRF 1 R activation;

d. selecting those test compounds that selectively activate CRF 2 R and further determining whether said test compound regulates muscle mass or function in a skeletal muscle atrophy model system; and

e. identifying those test compounds that regulate muscle mass or function as candidate compounds for regulating skeletal muscle mass or function.

8. The method according to claim 7 wherein the candidate compound exhibits a 100-fold or greater selectivity for CRF 2 R.

9. The method according to claim 7 wherein the candidate compound exhibits a 1000-fold or greater selectivity for CRF 2 R.

10. The method according to claim 7 wherein the candidate compound exhibits between 1-fold and 100-fold selectivity for CRF 2 R.

Assignments (5)
CORRECTIVE ASSIGNMENT TO CORRECT THE US PATENT NO. 8,050,873 PREVIOUSLY RECORDED ON REEL 040183 FRAME 0129. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Feb 22, 2018
From: WARNER CHILCOTT COMPANY, LLC
To: ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED
Reel/Frame 045417/0593 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 29, 2016
From: WARNER CHILCOTT COMPANY, LLC
To: ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED
Reel/Frame 040183/0129 →
RELEASE OF SECURITY INTEREST Recorded Oct 31, 2013
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: WARNER CHILCOTT COMPANY, LLC
Reel/Frame 031531/0538 →
RELEASE - REEL 023456, FRAME 0052 Recorded Mar 29, 2011
From: CREDIT SUISSSE AG, CAYMAN ISLANDS BRANCH, AS ADMINISTRATIVE AGENT
To: WARNER CHILCOTT COMPANY LLC
Reel/Frame 026042/0046 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 8, 2010
From: PROCTER & GAMBLE COMPANY, THE
To: WARNER CHILCOTT COMPANY, LLC
Reel/Frame 023796/0417 →